autologous dendritic cells (Oslo University Hospital)

This investigational autologous dendritic cell-based cancer vaccine is being developed by Oslo University Hospital for the treatment of untreated or relapsed indolent non-Hodgkin lymphoma (iNHL), including follicular lymphoma. The therapeutic approach, evaluated in the Lymvac-1 Phase II clinical trial, utilizes an "in situ" vaccination strategy. The patient's own dendritic cells are harvested, matured, and then injected intratumorally into a lymph node that has been pre-treated with low-dose radiotherapy (8 Gy) and the anti-CD20 monoclonal antibody rituximab. The radiotherapy and rituximab are intended to induce immunogenic tumor cell death and the release of tumor-associated antigens, which the injected dendritic cells then capture, process, and present to the immune system. This process is designed to prime a systemic, T-cell-mediated anti-tumor response capable of targeting both the injected lesion and distant, non-irradiated tumor sites.

Other names

autologous dendritic cell vaccineDC vaccineLymvac-1 vaccineLymvac1 vaccineLymvac 1 vaccine